Sort   by:  
 Page size 
UnknownClinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity.
Not available
S-EPMC9606350 | biostudies-literature
UnknownLinagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Not available
S-EPMC3411498 | biostudies-literature
UnknownThe Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
Not available
S-EPMC5954590 | biostudies-literature
UnknownGLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015.
Not available
S-EPMC5819057 | biostudies-literature
UnknownClinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Not available
S-EPMC8276717 | biostudies-literature
UnknownThe incretin/glucagon system as a target for pharmacotherapy of obesity.
Not available
S-EPMC9286339 | biostudies-literature
UnknownVariability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.
Not available
S-EPMC5697639 | biostudies-literature
UnknownDeletion of Von Hippel-Lindau Interferes with Hyper Osmolality Induced Gene Expression and Induces an Unfavorable Gene Expression Pattern.
Not available
S-EPMC7073186 | biostudies-literature
UnknownDissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans.
Not available
S-EPMC4731733 | biostudies-literature
UnknownLong-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Not available
S-EPMC4558893 | biostudies-literature
Sort   by:  
 Page size